TOCA News and Press, Tocagen From 02/27/20

SAN DIEGO , Feb. 27, 2020 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019 . "Following our extensive...

NGM Biopharmaceuticals (NASDAQ: NGM ) +67%  after aldafermin phase 2 results . More news on: NGM Biopharmaceuticals, Inc., NanoViricides, Inc., Enlivex Therapeutics Ltd., Stocks on the move, , Read more ...

Tocagen Inc. (TOCA) Tocagen and Forte Biosciences Announce Merger Conference Call February 20, 2020 08:30 AM ET Company Participants Marty Duvall - Chief Executive Officer, Tocagen Paul Wagner - Chief Executive Officer, Forte Presentation Operator Ladies and gentlemen, th...

5 Penny Stocks To Watch Right Now In the stock market today there are several things in focus that have driven broader markets lower and speculative stock higher. Concerns over the spread of the coronavirus continue to spin. On top of this, comments from the Federal Reserve have also been a...

Are These The Best Penny Stocks To Buy For Under $3 Right Now? Penny stocks are highly speculative and highly volatile. But the one thing all of these cheap stocks have in common is the price. According to the Securities and Exchange Commission’s definition of penny stocks , these ar...

SAN DIEGO and TORRANCE, Calif. , Feb. 19, 2020 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced t...

Are Any Of These Penny Stocks On Your Watch List This Month? This week we saw something pivotal in the U.S. economy that could set the tone for 2020. Wednesday saw Federal Reserve Chairman Jerome Powell said the central bank’s attempt to ease the financial markets was working. What ...

SAN DIEGO , Nov. 22, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (...

SAN DIEGO , Nov. 12, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019 . "Following the topline readout of our ...

Tocagen (NASDAQ: TOCA ): Q3 GAAP EPS of -$0.78 misses by $0.06 . More news on: Tocagen Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...